Lihui Bai

Goodwin

Contact
View Bio
RSS

Latest Posts › Korea

Share:

Alteogen Seeks Approval for Aflibercept Biosimilar in Korea

​​​​​​​On September 13, 2024, Alteogen announced that it has applied for marketing authorization in Korea for ALT-L9, an aflibercept biosimilar of EYLEA®. According to Alteogen, a 12-country Phase 3 study showed that ALT-L9...more

9/18/2024  /  Biosimilars , Korea , Marketing Authorization Application , Pharmaceutical Industry , Pharmaceutical Patents , Prescription Drugs
1 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide